The Effect of Escitalopram in PCOS

• Status: Completed
• Trial end date: 2017-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

In a randomized study the investigators aim to characterize the effect of antidepressive medicine on quality of life, body composition, adrenal activity and glucose metabolism in PCOS.

PCOS is a common endocrine disorder characterized by adrenal and ovarian hyperandrogenaemia, anovulation and insulin resistance. The pathogenesis of PCOS may be described by a vicious cycle involving insulin resistance which stimulates ovarian and adrenal hyper androgenaemia and leads to abdominal obesity, causing increased risk for diabetes and cardiovascular disease. Adrenal hyperactivity is associated with depression. Antidepressive medicine may normalize pituitary-adrenal activity and in animal studies antidepressive medicine improved adrenal hyperactivity and normalized insulin sensitivity.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Odense University Hospital
• Treatments: Citalopram

Criteria

Inclusion Criteria:

• BMI > 25 and <5

• Age 18-45 years

• Two of the following 1: an/oligomenorhea, 2: Hirsutism or hyper androgenaemia, 3: PCO in trans vaginal ultrasound

• Other diagnoses excluded

Exclusion Criteria:

• Post menopausal

• Diabetes

• Eating disorder

• Psychiatric disorder

• Usage of oral anticonceptives or metformin

• Pregnancy or planned pregnancy in the treatment period

• Non-caucasian

• Epilepsy

• Allergy to the medicine